CDK5RAP2: A Potential Drug Target and Biomarker for Cancer (G55755)

Target Name: CDK5RAP2

NCBI ID: G55755

CDK5RAP2

CDK5RAP2: A Potential Drug Target and Biomarker for Cancer

Abstract:

CDK5RAP2, a member of the CDK5 regulatory subunit associated protein 2 family, has been identified as a potential drug target and biomarker for cancer. Its expression has been observed in various types of cancer, including breast, ovarian, and colorectal cancers. CDK5RAP2 has been shown to play a role in cell signaling, and its levels have been associated with cancer progression. Further research is needed to understand the exact mechanism of action of CDK5RAP2 as a drug target and to explore its potential as a biomarker for cancer diagnosis and treatment.

Introduction:

CDK5RAP2, or CDK5 regulatory subunit associated protein 2, is a protein that is expressed in various tissues and cells, including cancer cells. It is a key component of the CDK5 signaling pathway, which is involved in cell signaling and division. The CDK5 signaling pathway is known to be involved in the development and progression of many types of cancer, including breast, ovarian, and colorectal cancers. Therefore, targeting CDK5RAP2 as a drug target or biomarker for cancer has the potential to provide new insights into the treatment of these cancers.

Expression of CDK5RAP2 in cancer cells:

CDK5RAP2 has been observed to be expressed in various types of cancer cells, including breast, ovarian, and colorectal cancers. In breast cancer, CDK5RAP2 has been shown to be involved in the regulation of cell cycle progression and the maintenance of cell stemness. In ovarian cancer, CDK5RAP2 has been associated with the development of resistance to chemotherapy. In colorectal cancer, CDK5RAP2 has been shown to be involved in the regulation of cell growth and the association with cancer stem cell properties.

CDK5RAP2 as a drug target:

CDK5RAP2 has been shown to play a role in cell signaling and has the potential to be a drug target for cancer. The CDK5 signaling pathway is involved in many cellular processes, including cell growth, cell cycle progression, and cell division. Therefore, targeting CDK5RAP2 as a drug target could potentially lead to the development of new cancer therapies.

One approach to targeting CDK5RAP2 is to use small molecules or antibodies to inhibit its activity. This could potentially lead to the inhibition of cell signaling and the regression of cancer cells. Another approach is to use drugs that specifically target CDK5RAP2, such as inhibitors of the CDK5RAP2-containing protein, or inhibitors of the activity of the CDK5RAP2-containing enzyme.

CDK5RAP2 as a biomarker:

CDK5RAP2 has also been shown to be a potential biomarker for cancer. Its expression has been associated with the development and progression of many types of cancer. Therefore, its levels can be used as a indicator of the severity and stage of cancer. This could potentially be used to identify patients who are at risk for more aggressive cancers and to guide the choice of treatment options.

CDK5RAP2 has also been shown to be involved in the regulation of cell signaling, which is a key factor in the development and progression of cancer. Therefore, its levels can be used as a biomarker for the effectiveness of different treatments. For example, if a patient has been treated with a cancer drug that inhibits CDK5RAP2, the levels of CDK5RAP2 can be used to assess the effectiveness of the treatment.

Conclusion:

CDK5RAP2 is a protein that has been observed to be expressed in various types of cancer cells. Its expression is involved in the regulation of cell signaling and has the potential to be a drug target for cancer. Further research is needed to understand the exact mechanism of action of CDK5RAP2 as a drug target and to explore its potential as a biomarker for cancer diagnosis and treatment.

Protein Name: CDK5 Regulatory Subunit Associated Protein 2

Functions: Potential regulator of CDK5 activity via its interaction with CDK5R1. Negative regulator of centriole disengagement (licensing) which maintains centriole engagement and cohesion. Involved in regulation of mitotic spindle orientation (By similarity). Plays a role in the spindle checkpoint activation by acting as a transcriptional regulator of both BUBR1 and MAD2 promoter. Together with EB1/MAPRE1, may promote microtubule polymerization, bundle formation, growth and dynamics at the plus ends. Regulates centrosomal maturation by recruitment of the gamma-tubulin ring complex (gamma-TuRC) onto centrosomes (PubMed:26485573). In complex with PDE4DIP isoform 13/MMG8/SMYLE, MAPRE1 and AKAP9, contributes to microtubules nucleation and extension from the centrosome to the cell periphery (PubMed:29162697). Required for the recruitment of AKAP9 to centrosomes (PubMed:29162697). Plays a role in neurogenesis (By similarity)

The "CDK5RAP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK5RAP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets